<DOC>
	<DOCNO>NCT02393157</DOCNO>
	<brief_summary>The purpose study determine safety administer obinutuzumab single agent alone combination ifosfamide , carboplatin , etoposide ( ICE ) chemotherapy determine response rate treatment child , adolescent young adult ( CAYA ) relapse CD20 positive B-cell Non-Hodgkin Lymphoma ( B-NHL ) .</brief_summary>
	<brief_title>Obinutuzumab ICE Chemotherapy Refractory/Recurrent CD20+ Mature NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patients first relapse primary induction failure CD20 positive Bcell leukemia/lymphoma include : Diffuse Large BCell Lymphoma Burkitt Lymphoma High Grade Bcell Lymphoma : Not Otherwise Specified ( NOS ) Primary mediastinal Bcell lymphoma ( PMBL ) CD20+ Blymphoblastic lymphoma Follicular lymphoma , Grade III Karnofsky ≥ 60 % patient &gt; 16 year age Lansky ≥ 60 patient ≤ 16 year age . Myelosuppressive chemotherapy : Must receive within 2 week entry onto study . Patients may receive prior therapy obinutuzumab ( GA101 ) Radiation Therapy ( XRT ) : Date receive prior XRT must &gt; 2 week local palliative XRT ( small port ) ; &gt; 6 month must elapse prior craniospinal XRT &gt; 50 % radiation pelvis ; &gt; 6 week must elapse substantial bone marrow radiation . Steroids : Patients may receive prior steroid treatment , start great 7 day prior initiation protocol therapy . Adequate organ function . Patients newly diagnose , previously untreated BNHL . Known congenital acquire immune deficiency . Prior solid organ transplantation . Prior allogeneic stem cell transplant within 60 day active acute GraftvsHostDisease ( GVHD ) grade 3 high . History grade 4 anaphylactic reaction humanize murine monoclonal antibody Uncontrolled hepatitis B and/or C infection</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>